French pharmaceutical company Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals in an all-cash transaction valued at approximately $2.5 billion. The deal, announced on March 6, 2026, represents a significant expansion of Servier's oncology portfolio, particularly in the rare disease segment.
Transaction Details and Premium
Servier will pay $21.50 per share in cash for all outstanding shares of Day One Biopharmaceuticals. This price represents a substantial 68% premium over Day One's closing price of $12.81 on March 5, 2026, just prior to the announcement. On Monday, March 9, 2026, Day One shares opened at $21.24, trading slightly below the offer price as market participants await the formal tender process.
The acquisition is structured as a tender offer that will proceed directly to Day One shareholders. The company's board of directors has unanimously approved the transaction and is recommending that shareholders tender their shares. Both companies anticipate completing the deal during the second quarter of 2026, subject to customary closing conditions.
Strategic Asset: Ojemda
The centerpiece of the acquisition is Ojemda (tovorafenib), Day One's flagship therapeutic asset. Ojemda holds distinction as the only monotherapy approved in the United States for the treatment of pediatric low-grade glioma, the most common form of brain tumor in children. This positions Servier for immediate entry into the pediatric neuro-oncology market.
The drug has demonstrated strong commercial performance, generating $155.4 million in sales during 2025. In February 2026, Day One reaffirmed its U.S. revenue guidance for Ojemda, projecting between $225 million and $250 million for the current year. The therapy is administered as a once-weekly dose, contrasting with the daily two-drug combination regimen of Novartis's competing Tafinlar and Mekinist.
Market Context and Growth Potential
Analysts view the acquisition as strategically sound for Servier. Wedbush analyst Robert Driscoll noted that Day One represented "an attractive take-out candidate," citing the successful launch of Ojemda and its potential for label expansion. The drug could see significantly increased utilization if it secures regulatory approval for earlier lines of treatment, possibly by 2028.
For Servier, the transaction aligns with its ambitious growth targets. The company aims to achieve annual revenues of 10 billion euros by 2030. This acquisition follows Servier's existing presence in the glioma space through Voranigo, its treatment for adult glioma, suggesting potential synergies across development and commercialization efforts.
Regulatory Progress and Global Footprint
The asset's value is further enhanced by recent regulatory advancements. On March 2, 2026, Day One reported that its European partner, Ipsen, received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. The committee recommended conditional marketing authorization for Ojemda in children with relapsed or refractory BRAF-altered pediatric low-grade glioma, paving the way for European approval.
Servier President Olivier Laureau characterized the deal as "another decisive step" in the company's strategic focus on rare oncology. Day One CEO Jeremy Bender stated that Servier provides the "ideal home" for both the company's portfolio and its team, ensuring the continued development and accessibility of their pediatric glioma therapy.
Closing Conditions and Potential Hurdles
While the transaction has been agreed upon, several steps remain before completion. According to securities filings, the formal tender offer has not yet commenced. The deal's closure is contingent upon a sufficient number of Day One shareholders tendering their shares and receiving clearance from U.S. antitrust authorities.
Day One's regulatory disclosures note potential obstacles, including the possibility of competing acquisition proposals, litigation related to the transaction, and operational disruptions among employees and business partners. No formal offer documents have been filed with regulators as of March 9, 2026.
The acquisition underscores the continued consolidation within the biotechnology sector, particularly for companies with approved, commercial-stage products in specialized therapeutic areas. Servier's move significantly bolsters its oncology pipeline and provides immediate revenue generation through Ojemda's established market presence.
